Trade Analytics

CIPLA

Go Back

CIPLA

  • Reduced the prices of cancer drugs, thus making world-class medicines affordable and accessible to cancer patients
  • Produced an anti-flu drug within a period of 2–3 months, which would have normally taken at least three years to develop
  • Pioneered the access to HIV treatment by making antiretrovirals (ARVs) available at less than a ‘dollar a day'
  • Manufactured the first transparent dry powder inhaler

Cipla began in 1935 when their founder Dr KA Hamid set up an enterprise with the vision to make India self-sufficient in healthcare.

Presently, they have 34 state-of-the-art manufacturing facilities that make Active Pharmaceutical Ingredients (APIs) and formulations, which have been approved by major international Regulatory Agencies, along with over 2000 products in 65 therapeutic categories. The company manufactures 40 dosage forms, covering a wide spectrum of diseases ranging from communicable, non-communicable, common and emerging diseases to even rare diseases.

Today, they are one of the world’s largest generic pharmaceutical companies with a strong presence in over 170 countries, with an assurance to maintain world-class quality across all their products and services.

Source: http://www.cipla.com

CIPLA: PROVIDING HEALTHCARE TO THE COUNTRY

2011 Receives ‘Outstanding Export Performance’ award in the export of pharmaceuticals and is conferred the highest award – ‘Platinum’
2007 Gets listed in Forbes Asia’s ‘Best under A Billon’
2006 Receives International Trade Award for Outstanding Exporter of The Year (pharmaceuticals, healthcare and life sciences category)
2006 Receives Silver Plate Award by Helpage India in 2006
2005 Receives Pharma Excellence Award for 'Sustained Growth'

Updated: June, 2014

Research and Development
India is presently ranked 76th among a total of 143 economies, as per the Global Innovation Index (GII).